- In September 2021, FDA had approved the first and only oral CGRP receptor antagonist named QULIPTA™ (atogepant), which is specifically developed for the preventive treatment of migraine. CGRP and its receptors are used for nervous system associated with migraine pathogenesis, and CGRP levels have been found to be higher during migraine attacks in studies. QULIPTA is a once-daily medication that blocks CGRP. It comes in three different strengths including 10 mg, 30 mg, and 60 mg
Frequently Asked Questions
The market is segmented based on Segmentation, By Types (Episodic, Chronic), Symptoms (Food Cravings, Depression, Fatigue, Frequent Yawning, Hyperactivity, Irritability, Neck Stiffness, Others), Treatment (Medication, Acupressure, Counseling, Hormone Therapy, Others), Diagnosis (Computerized Tomography (CT) Scan, Magnetic Resonance Imaging (MRI), Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2032
.
The Global Migraine Market size was valued at USD 3.95 USD Billion in 2024.
The Global Migraine Market is projected to grow at a CAGR of 4.1% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
